即时凝血检测产品市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球即时凝血检测产品市场价值为 28 亿美元，预计到 2034 年将以 6.2% 的复合年增长率成长，达到 52 亿美元。这些创新设备透过直接在床边或临床护理点提供即时凝血评估，从而无需进行中央实验室测试，从而改变了患者护理。随着人们越来越依赖即时可靠的结果，这些设备现在已成为紧急情况、外科手术和慢性病长期管理中不可或缺的一部分。市场的成长是由心血管疾病和血液疾病发病率的增加以及对快速诊断和即时监控的需求的增加所推动的。随着医疗保健提供者转向这些工具来支持关键的医疗决策，全球对凝血检测产品的需求正在加剧。此外，向分散医疗模式和可携式诊断设备的转变进一步推动了市场的扩张。这些工具不仅优化了工作流程，而且还透过及时介入改善了患者的治疗效果。

市场根据测试类型进行细分，包括活化凝血时间、D-二聚体测试、血小板计数、凝血酶原时间测试和其他类别。其中，凝血酶原时间检测领域占据领先地位，2024 年产值达 10 亿美元。预计 2025 年至 2034 年期间的复合年增长率为 6.3%。该领域的主导地位主要归功于其能够提供快速且可操作的资料，帮助医生精确调整抗凝血剂剂量。在凝血监测延迟可能导致严重併发症的情况下，凝血酶原时间测试提供的快速可靠的结果对于制定临床决策至关重要，特别是在重症监护和长期治疗管理中。

就产品类型而言，市场分为仪器和耗材，其中仪器在 2024 年占据 63% 的份额。预计到 2034 年，该细分市场将产生 33 亿美元的产值，因为仪器因其能够提供即时结果，从而提高高压临床环境中的效率而备受青睐。它们的便携性和与数位医疗系统的无缝整合使它们在医院和门诊环境中不可或缺，快速凝固特征对于挽救生命的干预至关重要。

2023 年，美国即时凝血检测产品市场规模达 8.514 亿美元。该地区市场的成长得益于慢性血液病患病率的上升，以及对即时诊断工具的需求不断增长。儘管监管协议严格，但由于有利的报销模式和渴望接受最新诊断创新的医疗保健基础设施，美国市场继续蓬勃发展。

雅培实验室、Sysmex Corporation、赛默飞世尔科技、西门子医疗、F. Hoffmann-La Roche 等领先企业处于这一成长的前沿。这些公司透过开发便携式、用户友好型、週转时间快的系统不断创新。他们在研究合作、新兴市场扩张以及云端连接增强方面的投资是增加市场占有率和改善全球临床结果的关键策略。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 慢性血液病患病率上升
    • 政府加强遏制血液相关疾病
    • 日益普及即时检测产品
    • 技术进步
  • 产业陷阱与挑战
    • 严格的监管框架
    • 产品开发成本高
• 成长潜力分析
• 监管格局
• 技术格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按测试类型，2021 - 2034 年

• 主要趋势
• 凝血酶原时间检测产品
• 活化凝血时间（ACT/APTT）检测产品
• 血小板计数
• D-二聚体检测
• 其他测试类型

第六章：市场估计与预测：依产品类型，2021 - 2034 年

• 主要趋势
• 仪器
• 耗材

第七章：市场估计与预测：依最终用途，2021 - 2034 年

• 主要趋势
• 医院
• 诊断中心
• 居家照护环境
• 其他最终用途

第八章：市场估计与预测：按地区，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Abbott Laboratories
• Alere
• A&T Corporation
• Diagnostica Stago Sas
• F. Hoffmann-La Roche
• Genrui Biotech
• Helena Laboratories
• Horiba
• Medtronic
• Nihon Kohden Corporation
• Micropoint Biosciences
• Maccura Biotechnology
• Sysmex Corporation
• Siemens Healthineers
• Thermo Fisher Scientific

The Global Point of Care Coagulation Testing Products Market was valued at USD 2.8 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 5.2 billion by 2034. These innovative devices are transforming patient care by providing real-time coagulation assessments directly at the bedside or clinical point of care, eliminating the need for central laboratory testing. With a growing reliance on immediate and reliable results, these devices are now integral in emergency situations, surgical procedures, and long-term management of chronic illnesses. The market's growth is driven by the increasing incidence of cardiovascular diseases and blood disorders, alongside the rising demand for rapid diagnoses and real-time monitoring. As healthcare providers turn to these tools to support critical medical decisions, the demand for coagulation testing products is intensifying globally. Moreover, the shift toward decentralized healthcare models and portable diagnostic devices further fuels the market's expansion. These tools not only optimize workflow but also enhance patient outcomes by enabling timely interventions.

The market is segmented based on test types, including activated clotting time, d-dimer tests, platelet count, prothrombin time testing, and other categories. Among these, the prothrombin time testing segment emerged as a leader, generating USD 1 billion in 2024. It is projected to grow at a CAGR of 6.3% between 2025 and 2034. The segment's dominance is primarily due to its ability to provide fast and actionable data that aids physicians in precisely adjusting anticoagulant dosages. In settings where delays in coagulation monitoring can lead to severe complications, the rapid and dependable results offered by prothrombin time tests have become critical in making clinical decisions, particularly in critical care and long-term therapy management.

In terms of product type, the market divides into instruments and consumables, with instruments holding a 63% share in 2024. This segment is expected to generate USD 3.3 billion by 2034, as instruments are highly favored for their ability to provide immediate results, thereby improving efficiency in high-pressure clinical environments. Their portability and seamless integration with digital healthcare systems make them indispensable in both hospital and outpatient settings, where quick coagulation profiles are essential for life-saving interventions.

The U.S. Point of Care Coagulation Testing Products Market generated USD 851.4 million in 2023. The market's growth in the region is supported by the rising prevalence of chronic hematologic conditions, coupled with a growing demand for real-time diagnostic tools. Despite stringent regulatory protocols, the U.S. market continues to thrive due to favorable reimbursement models and a healthcare infrastructure that is eager to embrace the latest diagnostic innovations.

Leading players such as Abbott Laboratories, Sysmex Corporation, Thermo Fisher Scientific, Siemens Healthineers, F. Hoffmann-La Roche, and others are at the forefront of this growth. These companies are continuously innovating by developing portable, user-friendly systems with rapid turnaround times. Their investment in research collaborations, expansion into emerging markets, and enhancement of cloud-based connectivity are key strategies to increase market presence and improve clinical outcomes globally.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chronic blood disorders
    • 3.2.1.2 Growing government initiatives to curb blood-related diseases
    • 3.2.1.3 Increasing adoption of point of care testing products
    • 3.2.1.4 Technological advancements
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory framework
    • 3.2.2.2 High cost of product development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter’s analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Prothrombin time testing products
• 5.3 Activated clotting time (ACT/APTT) testing products
• 5.4 Platelet count
• 5.5 D-dimer test
• 5.6 Others test types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Instruments
• 6.3 Consumables

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic centers
• 7.4 Home care settings
• 7.5 Other end use

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Alere
• 9.3 A&T Corporation
• 9.4 Diagnostica Stago Sas
• 9.5 F. Hoffmann-La Roche
• 9.6 Genrui Biotech
• 9.7 Helena Laboratories
• 9.8 Horiba
• 9.9 Medtronic
• 9.10 Nihon Kohden Corporation
• 9.11 Micropoint Biosciences
• 9.12 Maccura Biotechnology
• 9.13 Sysmex Corporation
• 9.14 Siemens Healthineers
• 9.15 Thermo Fisher Scientific